2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧23 min
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
171
Myynti
Määrä
600
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 077 | - | - | ||
| 51 | - | - | ||
| 996 | - | - | ||
| 1 055 | - | - | ||
| 1 055 | - | - |
Ylin
9,58VWAP
Alin
9,2VaihtoMäärä
1,3 138 606
VWAP
Ylin
9,58Alin
9,2VaihtoMäärä
1,3 138 606
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenDear Mormonsen 🤡 It's fascinating how you manage to make 6 become 2. New mathematical branch? “Mormonsk arithmetic”? Let's take it slowly: At the previous NeoLIPA presentation: 9 patients. As of February 2026: 15 patients. 15 minus 9 is… hold on tight… 6. Not 2. Not “approx. the same”. But six. You have been called both a manipulator and a charlatan, but honestly, those are almost a bit exaggerated titles for you. That presupposes a certain skill and talent! What you're doing is pure Clownery, plain and simple. “Clown” now feels like a more precise adjective for you!!
·31 min sittenI assume that Radiumhospitalet was inactive for at least half of December regarding the Neo-Lipa study. There was also minimal recruitment during the summer months.
·2 päivää sitten · MuokattuThis was sad stuff. Only 2 patients enrolled in NeoLipa since November until now. Actually absolutely terrible!!! Is it cherry picking of the patients that makes it go so slowly or what is the problem? Incredibly weak that measures haven't been implemented long ago, as Lytix has been challenged on this over 8 months ago. Incompetent. Guiding now changed from mid 2026 to end 2026. Unfortunately, I guess there will be yet another postponement here, and that one must wait until 2027 before the study is fully enrolled and read out. As the CFO said at the presentation: "NeoLIPA is our key value driver." Nothing new from Verrica, so maybe 2027 or 2028 before things loosen up there. TTT. As clanz and others have pointed out earlier, it takes time to prepare partner agreements. For Verrica, 1.5 years have passed since the phase 2 data were presented. One must probably expect the same to be the case for NeoLIPA, so it could take 1.5 years from top line data in 2027 until an agreement can be ready. TTT. A year of rest with lots of options and solid salary this year then. Great. Talk in 2027, but first another emission this summer / autumn is my assumption. After this year's general meeting, the board can run a new emission at any time, and it now looks like the new competent chairman is aware of raising money when one can, and not when one must.
·2 päivää sittenMormonsen does not follow the congregation, and it's good that some are critical. It will take a long time before the company comes with any share price driving news. Even though pastor rekdal preaches to the congregation and is very positive - it's good that some are critical of the company. It's allowed to be enthusiastic about what rekdal preached today - but he is obliged to be positive about everything. As of today, Hartviksen verrica hasn't landed anything at all, neolipa is slowly moving forward, and Lytix needs to open another hospital to reach its goal. No clear answers came today, just more promises and obfuscation. Changing the company form has nothing to do with listing on Oslo børs. Personally, I was disappointed by what emerged today. Keep it up, mormonsen, and be critical - but when you present facts, they must be correct.
·2 päivää sittenHave reviewed the Q4 presentation. The NeoLIPA data still holds up strongly with 44 % complete response and a high overall response rate. At the same time, the financing seems more secure after the January emission, which provides reassurance towards further development and partner dialogues. To me, the case looks more mature now than a year ago.- ·2 päivää sittenToday's message only confirms one thing - syrup company. 1.5 years after verrica's very good data, it's mostly status quo in the company. Things are really starting to drag out.
·2 päivää sittenAlways someone who has a longer horizon than 3 days in a stock. - ·10.2. · MuokattuThen one knows the fact regarding the claim by some that there is a lack of sellers. Unfortunately, there is rather a significant lack of buyers. A total of 1.5 million available shares at 9kr each remained unsold even though they were on offer. The fact is that there is a lack of buying interest in Lytix. Then we will soon know the fact about listing on the main list of Oslo Børs or not. Rekdal will answer Thursday. Then one also knows who spreads false information and becomes hysterical that the FACT emerges. Verrica is falling like a stone tonight. It does not look promising.·3 päivää sittenYou almost have to bother asking questions yourselves instead of thinking someone else will do it for you. Verrica is also falling sharply today. Sad that nothing more has happened around phase3 BCC. If recruitment in NeoLipa is still weak and they haven't managed as many as 18 patients by now, then there will be no results there before Christmas. A new postponement will be a new tragic low point. I'd rather wait until after the next emission comes this summer before I consider entering in the autumn. I hope they don't get a rejection on their patent application, but it's dragging on.
·3 päivää sittenIt is perfectly fair to ask critical questions, but some things should be kept separate. 1. Verrica and share price development Verrica is affected by far more factors than VP-315 alone. The Lytix program is currently only a minor part of Verrica's total pipeline and valuation. Day-to-day price movements therefore say little about the probability of a Phase 3 start-up. It is also worth noting that the stock has been well up in the last three months after their financing was strengthened. Short-term volatility changes neither regulatory status nor study design. 2. Phase 3 BCC and why financing takes time The study design has already been regulatory clarified. What remains is the financing structure and operational start-up. Financing a Phase 3 study in the USA typically involves negotiations on structure (royalty financing, partnership, debt, or combinations), due diligence, legal work, and approvals. Such processes often take months, not weeks, even when the parties are positive. The absence of a start-up as of today therefore does not mean that the project has been shelved, but that the capital structure must be put in place on the right terms. 3. NeoLIPA recruitment There are no publicly updated figures beyond what has been communicated. Concluding that recruitment is “sluggish” without new information becomes speculation. A potential delay will affect timing, but not the rights position or retained field. 4. Patents The prospectus discusses IP strategy and pending applications, but no rejections have been communicated. Patent processes often take several years, especially within formulation and oncology. That the processing time is extended is normal and not in itself a negative signal. 5. New share issue this summer The company has communicated runway into 2027. This significantly reduces the probability of short-term capital needs. Strategic share issues can never be ruled out in biotech, but as of now, there are no indications of an imminent need. In summary: There is risk in the case, particularly related to timing and financing. But several of the points raised here are currently assumptions, not confirmed facts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenDear Mormonsen 🤡 It's fascinating how you manage to make 6 become 2. New mathematical branch? “Mormonsk arithmetic”? Let's take it slowly: At the previous NeoLIPA presentation: 9 patients. As of February 2026: 15 patients. 15 minus 9 is… hold on tight… 6. Not 2. Not “approx. the same”. But six. You have been called both a manipulator and a charlatan, but honestly, those are almost a bit exaggerated titles for you. That presupposes a certain skill and talent! What you're doing is pure Clownery, plain and simple. “Clown” now feels like a more precise adjective for you!!·31 min sittenI assume that Radiumhospitalet was inactive for at least half of December regarding the Neo-Lipa study. There was also minimal recruitment during the summer months.
- ·2 päivää sitten · MuokattuThis was sad stuff. Only 2 patients enrolled in NeoLipa since November until now. Actually absolutely terrible!!! Is it cherry picking of the patients that makes it go so slowly or what is the problem? Incredibly weak that measures haven't been implemented long ago, as Lytix has been challenged on this over 8 months ago. Incompetent. Guiding now changed from mid 2026 to end 2026. Unfortunately, I guess there will be yet another postponement here, and that one must wait until 2027 before the study is fully enrolled and read out. As the CFO said at the presentation: "NeoLIPA is our key value driver." Nothing new from Verrica, so maybe 2027 or 2028 before things loosen up there. TTT. As clanz and others have pointed out earlier, it takes time to prepare partner agreements. For Verrica, 1.5 years have passed since the phase 2 data were presented. One must probably expect the same to be the case for NeoLIPA, so it could take 1.5 years from top line data in 2027 until an agreement can be ready. TTT. A year of rest with lots of options and solid salary this year then. Great. Talk in 2027, but first another emission this summer / autumn is my assumption. After this year's general meeting, the board can run a new emission at any time, and it now looks like the new competent chairman is aware of raising money when one can, and not when one must.·2 päivää sittenMormonsen does not follow the congregation, and it's good that some are critical. It will take a long time before the company comes with any share price driving news. Even though pastor rekdal preaches to the congregation and is very positive - it's good that some are critical of the company. It's allowed to be enthusiastic about what rekdal preached today - but he is obliged to be positive about everything. As of today, Hartviksen verrica hasn't landed anything at all, neolipa is slowly moving forward, and Lytix needs to open another hospital to reach its goal. No clear answers came today, just more promises and obfuscation. Changing the company form has nothing to do with listing on Oslo børs. Personally, I was disappointed by what emerged today. Keep it up, mormonsen, and be critical - but when you present facts, they must be correct.
- ·2 päivää sittenHave reviewed the Q4 presentation. The NeoLIPA data still holds up strongly with 44 % complete response and a high overall response rate. At the same time, the financing seems more secure after the January emission, which provides reassurance towards further development and partner dialogues. To me, the case looks more mature now than a year ago.
- ·2 päivää sittenToday's message only confirms one thing - syrup company. 1.5 years after verrica's very good data, it's mostly status quo in the company. Things are really starting to drag out.·2 päivää sittenAlways someone who has a longer horizon than 3 days in a stock.
- ·10.2. · MuokattuThen one knows the fact regarding the claim by some that there is a lack of sellers. Unfortunately, there is rather a significant lack of buyers. A total of 1.5 million available shares at 9kr each remained unsold even though they were on offer. The fact is that there is a lack of buying interest in Lytix. Then we will soon know the fact about listing on the main list of Oslo Børs or not. Rekdal will answer Thursday. Then one also knows who spreads false information and becomes hysterical that the FACT emerges. Verrica is falling like a stone tonight. It does not look promising.·3 päivää sittenYou almost have to bother asking questions yourselves instead of thinking someone else will do it for you. Verrica is also falling sharply today. Sad that nothing more has happened around phase3 BCC. If recruitment in NeoLipa is still weak and they haven't managed as many as 18 patients by now, then there will be no results there before Christmas. A new postponement will be a new tragic low point. I'd rather wait until after the next emission comes this summer before I consider entering in the autumn. I hope they don't get a rejection on their patent application, but it's dragging on.·3 päivää sittenIt is perfectly fair to ask critical questions, but some things should be kept separate. 1. Verrica and share price development Verrica is affected by far more factors than VP-315 alone. The Lytix program is currently only a minor part of Verrica's total pipeline and valuation. Day-to-day price movements therefore say little about the probability of a Phase 3 start-up. It is also worth noting that the stock has been well up in the last three months after their financing was strengthened. Short-term volatility changes neither regulatory status nor study design. 2. Phase 3 BCC and why financing takes time The study design has already been regulatory clarified. What remains is the financing structure and operational start-up. Financing a Phase 3 study in the USA typically involves negotiations on structure (royalty financing, partnership, debt, or combinations), due diligence, legal work, and approvals. Such processes often take months, not weeks, even when the parties are positive. The absence of a start-up as of today therefore does not mean that the project has been shelved, but that the capital structure must be put in place on the right terms. 3. NeoLIPA recruitment There are no publicly updated figures beyond what has been communicated. Concluding that recruitment is “sluggish” without new information becomes speculation. A potential delay will affect timing, but not the rights position or retained field. 4. Patents The prospectus discusses IP strategy and pending applications, but no rejections have been communicated. Patent processes often take several years, especially within formulation and oncology. That the processing time is extended is normal and not in itself a negative signal. 5. New share issue this summer The company has communicated runway into 2027. This significantly reduces the probability of short-term capital needs. Strategic share issues can never be ruled out in biotech, but as of now, there are no indications of an imminent need. In summary: There is risk in the case, particularly related to timing and financing. But several of the points raised here are currently assumptions, not confirmed facts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
171
Myynti
Määrä
600
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 077 | - | - | ||
| 51 | - | - | ||
| 996 | - | - | ||
| 1 055 | - | - | ||
| 1 055 | - | - |
Ylin
9,58VWAP
Alin
9,2VaihtoMäärä
1,3 138 606
VWAP
Ylin
9,58Alin
9,2VaihtoMäärä
1,3 138 606
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenDear Mormonsen 🤡 It's fascinating how you manage to make 6 become 2. New mathematical branch? “Mormonsk arithmetic”? Let's take it slowly: At the previous NeoLIPA presentation: 9 patients. As of February 2026: 15 patients. 15 minus 9 is… hold on tight… 6. Not 2. Not “approx. the same”. But six. You have been called both a manipulator and a charlatan, but honestly, those are almost a bit exaggerated titles for you. That presupposes a certain skill and talent! What you're doing is pure Clownery, plain and simple. “Clown” now feels like a more precise adjective for you!!·31 min sittenI assume that Radiumhospitalet was inactive for at least half of December regarding the Neo-Lipa study. There was also minimal recruitment during the summer months.
- ·2 päivää sitten · MuokattuThis was sad stuff. Only 2 patients enrolled in NeoLipa since November until now. Actually absolutely terrible!!! Is it cherry picking of the patients that makes it go so slowly or what is the problem? Incredibly weak that measures haven't been implemented long ago, as Lytix has been challenged on this over 8 months ago. Incompetent. Guiding now changed from mid 2026 to end 2026. Unfortunately, I guess there will be yet another postponement here, and that one must wait until 2027 before the study is fully enrolled and read out. As the CFO said at the presentation: "NeoLIPA is our key value driver." Nothing new from Verrica, so maybe 2027 or 2028 before things loosen up there. TTT. As clanz and others have pointed out earlier, it takes time to prepare partner agreements. For Verrica, 1.5 years have passed since the phase 2 data were presented. One must probably expect the same to be the case for NeoLIPA, so it could take 1.5 years from top line data in 2027 until an agreement can be ready. TTT. A year of rest with lots of options and solid salary this year then. Great. Talk in 2027, but first another emission this summer / autumn is my assumption. After this year's general meeting, the board can run a new emission at any time, and it now looks like the new competent chairman is aware of raising money when one can, and not when one must.·2 päivää sittenMormonsen does not follow the congregation, and it's good that some are critical. It will take a long time before the company comes with any share price driving news. Even though pastor rekdal preaches to the congregation and is very positive - it's good that some are critical of the company. It's allowed to be enthusiastic about what rekdal preached today - but he is obliged to be positive about everything. As of today, Hartviksen verrica hasn't landed anything at all, neolipa is slowly moving forward, and Lytix needs to open another hospital to reach its goal. No clear answers came today, just more promises and obfuscation. Changing the company form has nothing to do with listing on Oslo børs. Personally, I was disappointed by what emerged today. Keep it up, mormonsen, and be critical - but when you present facts, they must be correct.
- ·2 päivää sittenHave reviewed the Q4 presentation. The NeoLIPA data still holds up strongly with 44 % complete response and a high overall response rate. At the same time, the financing seems more secure after the January emission, which provides reassurance towards further development and partner dialogues. To me, the case looks more mature now than a year ago.
- ·2 päivää sittenToday's message only confirms one thing - syrup company. 1.5 years after verrica's very good data, it's mostly status quo in the company. Things are really starting to drag out.·2 päivää sittenAlways someone who has a longer horizon than 3 days in a stock.
- ·10.2. · MuokattuThen one knows the fact regarding the claim by some that there is a lack of sellers. Unfortunately, there is rather a significant lack of buyers. A total of 1.5 million available shares at 9kr each remained unsold even though they were on offer. The fact is that there is a lack of buying interest in Lytix. Then we will soon know the fact about listing on the main list of Oslo Børs or not. Rekdal will answer Thursday. Then one also knows who spreads false information and becomes hysterical that the FACT emerges. Verrica is falling like a stone tonight. It does not look promising.·3 päivää sittenYou almost have to bother asking questions yourselves instead of thinking someone else will do it for you. Verrica is also falling sharply today. Sad that nothing more has happened around phase3 BCC. If recruitment in NeoLipa is still weak and they haven't managed as many as 18 patients by now, then there will be no results there before Christmas. A new postponement will be a new tragic low point. I'd rather wait until after the next emission comes this summer before I consider entering in the autumn. I hope they don't get a rejection on their patent application, but it's dragging on.·3 päivää sittenIt is perfectly fair to ask critical questions, but some things should be kept separate. 1. Verrica and share price development Verrica is affected by far more factors than VP-315 alone. The Lytix program is currently only a minor part of Verrica's total pipeline and valuation. Day-to-day price movements therefore say little about the probability of a Phase 3 start-up. It is also worth noting that the stock has been well up in the last three months after their financing was strengthened. Short-term volatility changes neither regulatory status nor study design. 2. Phase 3 BCC and why financing takes time The study design has already been regulatory clarified. What remains is the financing structure and operational start-up. Financing a Phase 3 study in the USA typically involves negotiations on structure (royalty financing, partnership, debt, or combinations), due diligence, legal work, and approvals. Such processes often take months, not weeks, even when the parties are positive. The absence of a start-up as of today therefore does not mean that the project has been shelved, but that the capital structure must be put in place on the right terms. 3. NeoLIPA recruitment There are no publicly updated figures beyond what has been communicated. Concluding that recruitment is “sluggish” without new information becomes speculation. A potential delay will affect timing, but not the rights position or retained field. 4. Patents The prospectus discusses IP strategy and pending applications, but no rejections have been communicated. Patent processes often take several years, especially within formulation and oncology. That the processing time is extended is normal and not in itself a negative signal. 5. New share issue this summer The company has communicated runway into 2027. This significantly reduces the probability of short-term capital needs. Strategic share issues can never be ruled out in biotech, but as of now, there are no indications of an imminent need. In summary: There is risk in the case, particularly related to timing and financing. But several of the points raised here are currently assumptions, not confirmed facts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
171
Myynti
Määrä
600
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 077 | - | - | ||
| 51 | - | - | ||
| 996 | - | - | ||
| 1 055 | - | - | ||
| 1 055 | - | - |
Ylin
9,58VWAP
Alin
9,2VaihtoMäärä
1,3 138 606
VWAP
Ylin
9,58Alin
9,2VaihtoMäärä
1,3 138 606
Välittäjätilasto
Dataa ei löytynyt